Intensity Therapeutics(INTS) - 2025 FY - Earnings Call Transcript

Financial Data and Key Metrics Changes - The meeting confirmed the approval of a reverse stock split of the company's common stock by a ratio of not less than one for five and not more than one for thirty, with the exact ratio to be determined by the Board of Directors [5][8]. Company Strategy and Development Direction - The company intends to implement the reverse stock split to potentially enhance the stock's marketability and attract institutional investors, although the specific timing and ratio will be decided at the Board's discretion [9]. Management's Comments on Operating Environment and Future Outlook - Management indicated that the decision regarding the reverse stock split will be made when deemed necessary, emphasizing the importance of timing and market conditions [9]. Other Important Information - A quorum was established with 22,631,128 shares present, representing 46.13% of the outstanding voting stock [4]. - The results of the voting will be disclosed in a current report on Form 8-K within four business days of the meeting [9]. Q&A Session Summary Question: When would the company decide to implement the reverse stock split and determine the number of shares to reduce it to? - Management stated that the decision will be made by the Board of Directors at the appropriate time, with the intention to act before any deadlines [9].